ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows
Arcturus Therapeutics stock (ARCT) surged nearly 20% due to positive sentiment surrounding its mRNA pipeline, including the regaining of global rights to its KOSTAIVE vaccine and a growing cash reserve of $191.5 million. Despite a slight revenue miss and continued losses in Q2, the company's strong balance sheet and advancing Phase 2 trials for ARCT-032 and ARCT-810 are providing catalysts for traders. Analysts maintain a "Buy" rating, seeing the recent collaboration changes and cash injection as beneficial for the company's future.
Liquidity Mapping Around (ARCT) Price Events
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a significant risk-reward short setup and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for ARCT.
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial health and potential need for future funding.
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase III in the fourth quarter, based on ongoing Phase II data. Additionally, Arcturus anticipates reporting data and regulatory updates for its injectable mRNA therapy for OTC deficiency (ARCT-810) before September 30, while maintaining a cash runway through 2028.
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9
H.C. Wainwright has reiterated its Hold rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $9. This indicates that the firm sees the stock as likely to perform in line with the broader market and does not anticipate significant price movement from current levels.
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23
BTIG has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its price target at $23. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen
Wall Street Zen upgraded Arcturus Therapeutics (ARCT) from "strong sell" to "sell," while Weiss Ratings maintained its "sell (D-)" rating. Despite these downgrades, MarketBeat's analyst consensus remains a "Moderate Buy" with an average price target of $24.25. The clinical-stage biotech company, which develops mRNA medicines and vaccines, reported a quarterly loss of $0.84 per share, beating expectations, but revenue of $2.96 million missed estimates.
Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS
Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE vaccine portfolio after ending a collaboration with CSL. Despite a sharp decline in revenue and cash, the company states it has sufficient cash runway through 2028.
Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside
Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains a "Buy," with 10 recommending Buy, 3 Hold, and 0 Sell. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20
CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics announced progress in its Q2 earnings call for 2026, advancing its rare-disease pipeline, completing enrollment for its Phase II OTC deficiency study, and regaining global rights to its KOSTAIVE COVID-19 vaccine and mRNA platform. The company also reported on its cystic fibrosis treatment candidate, ARCT-032, and its financial position, including cash and cash equivalents of $191.5 million as of June 30. Revenue decreased due to the end of the CSL collaboration, but the company's cash runway extends through the end of 2028.
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVE® and its infectious disease vaccine portfolio, receiving $12 million in cash and $16 million in released liabilities. Despite a decrease in revenue compared to the previous year, Arcturus maintains a strong cash position with a runway through 2028, supported by strategic collaborations and a focus on rare disease programs.
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view
Arcturus Therapeutics reported a narrower-than-expected loss for Q2 2026, beating EPS forecasts by 20%, but saw a significant revenue drop due to the conclusion of its CSL Seqirus collaboration. The company emphasized progress in its rare disease pipeline, including cystic fibrosis (ARCT-032) and ornithine transcarbamylase deficiency (ARCT-810) programs, with key clinical milestones expected later in 2026. Arcturus also regained global rights to its KOSTAIVE COVID-19 vaccine and broader self-amplifying mRNA platform, exploring new commercialization and partnering opportunities.
Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary
Arcturus Therapeutics Holdings Inc. (ARCT) reported its Q2 2026 financial results, with revenue of $2.96 million and a net loss of $23.79 million, resulting in a diluted loss per share of $(0.84). This decline in revenue is attributed to KOSTAIVE transitioning to commercial stages, leading to a significant drop in collaboration and grant revenue. Despite the financial decline, the company highlighted product momentum with KOSTAIVE's approval in Japan, ongoing clinical progress for ARCT-032 and ARCT-810, and strategic manufacturing partnerships.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) reported a Q2 loss of $0.84 per share, surpassing the Zacks Consensus Estimate of a $1.07 loss, and beat revenue estimates with $2.96 million. Despite underperforming the S&P 500 year-to-date, the company has exceeded EPS estimates in three of the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the market.
Why (ARCT) Price Action Is Critical for Tactical Trading
The article discusses the critical price action for Arcturus Therapeutics Holdings Inc. (ARCT) for tactical trading, highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 394.0:1 risk-reward setup targeting a 90.6% gain versus 0.2% risk and provides three distinct institutional trading strategies based on AI models: Position, Momentum Breakout, and Risk Hedging. The analysis also includes a multi-timeframe signal analysis indicating support and resistance levels across different time horizons.
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview
Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 100 cents per share in its upcoming earnings. This forecast is part of an earnings preview, suggesting investors and analysts are closely watching the company's financial performance. The full article provides more in-depth analysis from Reuters, accessible through a TradingView subscription.
Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Arcturus Therapeutics Holdings Inc (ARCT), detailing its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, its beta value compared to the S&P 500 index, and various financial metrics such as maximum drawdown, volatility, and liquidity. The assessment indicates that ARCT tends to outperform during upward markets but experiences larger declines during downward trends.
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its second-quarter financial results for 2026 on Thursday, August 6th, after market close. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide a corporate update. Arcturus is a messenger RNA medicines company focusing on liver and respiratory rare disease therapeutics, known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine.
Arcturus Therapeutics Q2 Results: Financials and update due Aug 6
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is scheduled to release its Q2 2026 financial results after market close on August 6, 2026, followed by a conference call at 4:30 p.m. ET for a corporate update. While no specific financial figures are in the pre-announcement, the call will cover the company's mRNA pipeline for rare diseases and pandemic vaccines. Investors can access the call via phone or webcast to gain insights into the company's strategic direction and therapeutic candidates.
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its second-quarter 2026 financial results after market close on Thursday, August 6th, and will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time. The company, a messenger RNA medicines focused on rare disease therapeutics, will also provide a corporate update during the event.
Arcturus Therapeutics Market Sentiment
This article provides an overview of market sentiment for Arcturus Therapeutics (ARCT), including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly higher than the current price, despite rising short interest. The report also highlights recent analyst actions and significant whale alerts related to the company.
Arcturus Therapeutics Holdings Inc
This article provides details on Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also offers general information about TradingKey's services and disclaimers regarding financial advice.
Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow
This article provides a detailed cash flow statement for Arcturus Therapeutics Holdings Inc (ARCT), covering quarterly and annual data from FY2012Q3 to FY2026Q1. It breaks down operating, investing, and financing cash flows, along with specific components like capital expenditures and changes in working capital. The detailed financial data helps evaluate the company's financial health and stability.
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT) focusing on its dividend and stock split history. It states that the company has not distributed dividends over the past five years. Key financial data like market capitalization and recent stock performance are also included.
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing its major shareholders and institutional holdings. Key shareholders include Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust Company, N.A., alongside data on institutional shareholding trends over recent quarters. The report also highlights ARCT's presence in various related ETFs.
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Arcturus Therapeutics Holdings Inc. (ARCT) on NASDAQ, showing its current stock price and performance. It indicates that Arcturus Therapeutics' stock is down by 4.84% at $5.79, with delayed prices. The page also presents a lack of current data for analyst ratings and earnings for ARCT.
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260
Arcturus Therapeutics Holdings Inc. (ARCT) closed at $5.530, down 4.49%. The company, focused on mRNA medicines and vaccines, has healthy fundamentals and significant growth potential, although its stock price has performed weakly recently. Analysts have given the stock an overall "Buy" rating with a target price of $19.89.
Arcturus Therapeutics Holdings Inc. Revenue Breakdown – NASDAQ:ARCT
This article provides a revenue breakdown for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). Last year, the company generated $82.03 million USD, primarily from its Messenger Ribonucleic Acid Medicines segment, and the largest contribution came from the United States. This marks a decrease from $152.31 million USD in the previous year.
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260
This article provides a financial summary of Arcturus Therapeutics Holdings Inc (ARCT), detailing its latest earnings report from May 7, 2026, and presenting historical quarterly and annual financial metrics. It covers key indicators such as EPS, revenue, net profit, various margins, and balance sheet items like assets, liabilities, and equity, offering an all-in-one data dashboard for investors. The article also includes frequently asked questions regarding the company's financial performance.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings, Actual EPS, EPS Estimates & Results
This article provides detailed earnings information for Arcturus Therapeutics Holdings Inc (ARCT), including its upcoming Q2 '26 earnings report, estimated EPS and revenue, and historical quarterly earnings data. It highlights past performance against estimates, showing both beats and misses. Additionally, the article includes recent news and trending discussions related to ARCT and other stocks.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, a messenger RNA medicines specialist, focuses on developing therapeutics for liver and respiratory rare diseases using its LUNAR®, STARR® mRNA technologies, and manufacturing expertise. Arcturus has a significant patent portfolio and collaborations, including one with CSL Seqirus and U.S. BARDA.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, an mRNA medicines developer, specializes in liver and respiratory rare disease therapeutics using LUNAR lipid-mediated delivery and STARR mRNA technology. Arcturus has a diverse pipeline including candidates for cystic fibrosis and ornithine transcarbamylase deficiency, in addition to partnered vaccine programs.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. ET. The company, focused on messenger RNA medicines for liver and respiratory rare diseases, will participate in a fireside chat. Arcturus is known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine, and has a robust pipeline including collaborations for pandemic flu and various RNA therapeutic candidates.
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20
Roth MKM has reiterated its Buy rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $20. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Arcturus Therapeutics Holdings Inc (ARCT), focusing on its price momentum, support and resistance levels, and key indicators. It highlights that ARCT's price momentum score is 4.35, placing it low within its industry, and the stock is trading between resistance at $7.68 and support at $5.69. The analysis of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages (MA5 to MA200) overwhelmingly suggests a "Sell" signal for the stock.
Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis
Arcturus Therapeutics (ARCT) is gaining attention for its inhaled mRNA therapeutic, ARCT-032, for cystic fibrosis, which is advancing to a pivotal Phase 2 study after promising early safety and mucus reduction data. The company has a robust mRNA platform, including self-amplifying mRNA and LUNAR® delivery, validated by the UK-approved COVID-19 vaccine, KOSTAIVE®. Despite being a high-risk, high-reward biotech play with a significant projected upside from Wall Street analysts, investors need to consider the inherent volatility and risks associated with clinical-stage biotech investments.
ARCT Should I Buy
This article analyzes whether Arcturus Therapeutics Holdings Inc (ARCT) is a good investment, concluding with a "Hold" recommendation for beginner long-term investors. While the stock benefits from supportive analyst coverage and a promising Thermo Fisher collaboration, its current technical setup is neutral, the company faces financial pressure, and it lacks clear momentum. Analyst ratings are positive, with price targets suggesting substantial upside, but the company's clinical-stage nature means valuation heavily relies on future trial success.
Arcturus Therapeutics (ARCT) 44th Annual J.P. Morgan Healthcare Conference Summary
Arcturus Therapeutics (ARCT) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its shift to a leaner organization focused on RNA medicines and LUNAR delivery technology. The company detailed progress in its Cystic Fibrosis (ARCT-032) and Ornithine Transcarbamylase (OTC) Deficiency (ARCT-810) programs, showcasing positive safety and efficacy data, regulatory designations, and upcoming study plans. Arcturus also noted its global COVID vaccine product approval and robust intellectual property portfolio.
Arcturus Therapeutics (ARCT) Q1 2025 earnings summary
Arcturus Therapeutics (ARCT) reported its Q1 2025 earnings, highlighting a prioritized mRNA therapeutics pipeline focused on cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs. The company achieved EU and Japan approvals for KOSTAIVE®, its self-amplifying mRNA COVID-19 vaccine, and has extended its cash runway into Q1 2028 through cost reductions and program prioritization. Financially, Q1 2025 revenue was $29.4 million, and the net loss narrowed to $14.1 million.
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23
BTIG has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its price target of $23. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Price to sales forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT
This page displays the "Price to sales forward" metric for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). It indicates that the market for ARCT was closed and no trades were recorded, providing various financial, news, and community tabs for further research.
If You Invested $1,000 in Arcturus Therape (ARCT)
This article examines the historical performance of a $1,000 investment in Arcturus Therapeutics (ARCT) over one, five, and ten years, showing significant losses across all periods, underperforming the S&P 500. It also provides a detailed overview of the company, highlighting its focus on mRNA medicines and vaccines for rare diseases and infectious diseases, its proprietary LUNAR® and STARR® platforms, and its clinical development pipeline including therapies for cystic fibrosis and OTC deficiency, and vaccines like KOSTAIVE®.
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial
Thermo Fisher Scientific has teamed up with Arcturus Therapeutics to advance ARCT-032, an investigational mRNA therapy for cystic fibrosis, into Phase III clinical trials. This collaboration will leverage Thermo Fisher's Accelerator Drug Development solutions for integrated manufacturing, clinical research, and commercial readiness. If positive Phase II results are achieved, Thermo Fisher will support the Phase III program through its PPD clinical research business and gain exclusive commercial manufacturing rights.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) stock jumped 5.7% after the company announced a strategic collaboration with Thermo Fisher Scientific for the phase III development and commercialization of its cystic fibrosis mRNA therapy, ARCT-032. While the stock saw a significant gain, its near-term outlook is cautious, holding a Zacks Rank #3 (Hold), due to unchanged consensus EPS estimates for the upcoming quarter despite strong revenue and earnings expectations. The article suggests investors monitor future earnings estimate revisions to determine if the recent strength will continue.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator™ Drug Development solutions for integrated manufacturing, clinical research, and commercial readiness services, supporting ARCT-032's Phase 3 development and potential commercialization. The agreement includes provisions for exclusive commercial manufacturing rights for Thermo Fisher if ARCT-032 receives regulatory approval.
ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy
Freedom Broker has initiated coverage on Arcturus Therapeutics (ARCT) with a "Buy" rating and a price target of $27.00. Despite this positive analyst outlook, GuruFocus assesses ARCT as 65.8% overvalued with a GF Value™ of $4.15 compared to its current market price of $6.88. The company's GF Score™ of 56/100 suggests moderate potential for long-term returns, balanced by a fair Financial Strength rating but lower Profitability and Growth ranks.
Freedom Capital Markets Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $27
Freedom Capital Markets has initiated coverage on Arcturus Therapeutics (ARCT.US) with a Buy rating. The firm has set a target price of $27 for the biotechnology company. This initiation suggests a positive outlook on Arcturus Therapeutics' future performance.
ARCT - Arcturus Therapeutics Holdings Inc Latest SEC Filings
This article provides key financial data and performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT), including its market capitalization, income, sales, per-share values, and various ratios. It also details the company's past and projected EPS and sales growth, insider and institutional ownership, and stock performance across different timeframes.
Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT
The article presents a financial data point for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a data visualization page from TradingView, indicating a value for this metric over a certain period.
